PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-53.09%
R&D reduction while CRVO shows 5.59% growth. Joel Greenblatt would examine competitive risk.
3.56%
G&A growth less than half of CRVO's 37.03%. David Dodd would verify if efficiency advantage is structural.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other expenses reduction while CRVO shows 100.00% growth. Joel Greenblatt would examine efficiency.
-26.91%
Operating expenses reduction while CRVO shows 251.41% growth. Joel Greenblatt would examine advantage.
-26.91%
Total costs reduction while CRVO shows 15.98% growth. Joel Greenblatt would examine advantage.
10.26%
Interest expense change of 10.26% while CRVO maintains costs. Bruce Berkowitz would investigate control.
-96.48%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-115.63%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
27.06%
Operating income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-198.08%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-304.05%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
113.79%
Tax expense change of 113.79% while CRVO maintains burden. Bruce Berkowitz would investigate strategy.
-304.05%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-302.06%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-288.66%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
0.11%
Share count reduction exceeding 1.5x CRVO's 2.84%. David Dodd would verify capital allocation.
3.68%
Diluted share reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.